BTG plc – Product Pipeline Review – 2013

Date: May 31, 2013
Pages: 81
Price:
US$ 1,500.00
License [?]:
Publisher: Global Markets Direct
Report type: Strategic Report
Delivery: E-mail Delivery (PDF)
ID: BD0A94DB351EN
Leaflet:

Download PDF Leaflet

BTG plc – Product Pipeline Review – 2013
BTG plc – Product Pipeline Review – 2013

Summary

Global Market Direct’s pharmaceuticals report, “BTG plc - Product Pipeline Review - 2013” provides data on the BTG plc’s research and development focus. The report includes information on current developmental pipeline, complete with latest updates, and features on discontinued and dormant projects.

This report is built using data and information sourced from Global Markets Direct’s proprietary databases, BTG plc’s corporate website, SEC filings, investor presentations and featured press releases, both from BTG plc and industry-specific third party sources, put together by Global Markets Direct’s team.

Scope
  • BTG plc - Brief BTG plc overview including business description, key information and facts, and its locations and subsidiaries.
  • Review of current pipeline of BTG plc human therapeutic division.
  • Overview of pipeline therapeutics across various therapy areas.
  • Coverage of current pipeline molecules in various stages of drug development, including the combination treatment modalities, across the globe.
  • Product profiles for late stage and clinical stage products of BTG plc with complete description of the product’s developmental history, mechanism of action, therapeutic class, target and major milestones.
  • Recent updates of the BTG plc’s pipeline in the last quarter.
  • Key discontinued and dormant projects.
  • Latest news and deals relating to the products.
Reasons to buy
  • Evaluate BTG plc’s strategic position with total access to detailed information on its product pipeline.
  • Assess the growth potential of BTG plc in its therapy areas of focus.
  • Identify new drug targets and therapeutic classes in the BTG plc’s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas.
  • Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps.
  • Exploit collaboration and partnership opportunities with BTG plc.
  • Avoid Intellectual Property Rights related issues.
  • Explore the dormant and discontinued projects of BTG plc and identify potential opportunities in those areas.
BTG plc Snapshot
BTG plc Overview
Key Information
Key Facts
BTG plc – Research and Development Overview
Key Therapeutic Areas
BTG plc – Pipeline Review
Pipeline Products by Stage of Development
Pipeline Products – Monotherapy
BTG plc – Pipeline Products Glance
BTG plc – Late Stage Pipeline
Registration Filed Products/Combination Treatment Modalities
BTG plc – Drug Profiles
glucarpidase
Product Description
Mechanism of Action
R&D Progress
polidocanol
Product Description
Mechanism of Action
R&D Progress
BTG plc – Pipeline Products by Route of Administration
BTG plc – Recent Pipeline Updates
BTG plc - Dormant Projects
BTG plc - Discontinued Pipeline Products
Discontinued Pipeline Product Profiles
(caricotamide + tretazicar)
AZD-9773
BGC-20-0166
BGC-20-0582
BGC-20-1259
BGC-200134
BTG-6001
BTG-6228
CM-3
BTG plc – Company Statement
BTG plc – Locations And Subsidiaries
Head Office
Other Locations & Subsidiaries
BTG plc, Recent Developments
BTG plc- Press Release
Apr 22, 2013: SCM Pharma Supports Clinical Scale-up Of BTG's Varisolve
Apr 12, 2013: BTG Announces FDA Acceptance Of NDA For Varisolve
Feb 04, 2013: BTG Submits NDA For Varisolve To FDA
Oct 25, 2010: AstraZeneca Initiates Phase IIB Study For AZD9773 As Treatment For Severe Sepsis
Sep 16, 2010: BTG Initiates First Varisolve US Phase III Trial For Treatment Of Varicose Veins
Aug 31, 2010: BTG Signs Agreement With Nycomed For Marketing Rights Of CroFab
Aug 31, 2010: BTG Signs Agreement With Nycomed For Marketing Rights Of DigiFab
Aug 13, 2010: Liver Metastases Clinical Trail Referenced By Cancer research UK
Feb 04, 2010: BTG Receives First European Regulatory Approval For DigiFab
Jan 21, 2010: BTG Plc Commences Phase IIa Study Of Pleneva For Multiple Sclerosis
Financial Deals Landscape
BTG plc, Deals Summary
BTG plc, Pharmaceuticals & Healthcare, Deal Details
Asset Transactions
BTG To Acquire Targeted Therapies Business Of Nordion For US$200 Million
Biocompatibles International Acquires Bead Technology Patents From BioCure
Biocompatibles International Completes Acquisition Of Cancer Diagnostic Products And Intellectual Property From Astron Clinica
BTG International Acquires Novel Opioid Agonist From CLL Pharma
Venture Financing
Xention Secures US$13 Million In Series D Venture Financing
Xention Discovery Secures US$3.4 Million In Series B Financing Round
Partnerships
Philips Partners Biocompatibles To Advance Image Guided Transarterial Embolizations In Interventional Oncology
MedX Health Enters Into An Agreement With Biocompatibles International
BTG Enters Into Co-Marketing Agreement With Nycomed
IsoRay Enters Into Distribution Agreement With Biocompatibles International
Biocompatibles Enters Into Co-Development Agreement With AstraZeneca
PolyTherics Expands Co-Development Agreement With Biocompatibles
Licensing Agreements
BTG Enters Into Licensing Agreement With Ohara Pharma For Glucarpidase
Ariel Pharma Enters Into Licensing Agreement With BTG International For AP-1531
BTG Enters Into Licensing Agreement With Wellstat Therapeutics For Uridine Triacetate
BTG Enters Into Licensing Agreement With Allergan
Eisai Enters Into Licensing Agreement With Biocompatibles International
BTG International Enters Into Licensing Agreement With Onyx Pharma
BTG Enters Into License Agreement With Novacea For AQ4N
Equity Offering
BTG Completes Private Placement Of Shares For US$160 Million
Asset Transactions
MedX Health Acquires Siascopy Assets From BTG For US$0.3 Million
BTG International Sells HySolv Drug Delivery Technology To Novartis Pharma
Acquisition
BTG To Acquire Ekos, Developer Of Drug Delivery System, For US$220 Million
BTG International Acquires Biocompatibles
BTG International Acquires Protherics
Biocompatibles International Completes Acquisition Of BrachySciences For US$21.4 Million
Novartis Acquires Protez Pharma From BTG International
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

LIST OF TABLES

BTG plc, Key Information
BTG plc, Key Facts
BTG plc – Pipeline by Indication, 2013
BTG plc – Pipeline by Stage of Development, 2013
BTG plc – Monotherapy Products in Pipeline, 2013
BTG plc – Filed, 2013
BTG plc – Pipeline By Route of Administration, 2013
BTG plc – Recent Pipeline Updates, 2013
BTG plc - Dormant Developmental Projects,2013
BTG plc - Discontinued Pipeline Products, 2013
BTG plc, Subsidiaries
BTG plc, Deals Summary
BTG To Acquire Targeted Therapies Business Of Nordion For US$200 Million
Biocompatibles International Acquires Bead Technology Patents From BioCure
Biocompatibles International Completes Acquisition Of Cancer Diagnostic Products And Intellectual Property From Astron Clinica
BTG International Acquires Novel Opioid Agonist From CLL Pharma
Xention Secures US$13 Million In Series D Venture Financing
Xention Discovery Secures US$3.4 Million In Series B Financing Round
Philips Partners Biocompatibles To Advance Image Guided Transarterial Embolizations In Interventional Oncology
MedX Health Enters Into An Agreement With Biocompatibles International
BTG Enters Into Co-Marketing Agreement With Nycomed
IsoRay Enters Into Distribution Agreement With Biocompatibles International
Biocompatibles Enters Into Co-Development Agreement With AstraZeneca
PolyTherics Expands Co-Development Agreement With Biocompatibles
BTG Enters Into Licensing Agreement With Ohara Pharma For Glucarpidase
Ariel Pharma Enters Into Licensing Agreement With BTG International For AP-1531
BTG Enters Into Licensing Agreement With Wellstat Therapeutics For Uridine Triacetate
BTG Enters Into Licensing Agreement With Allergan
Eisai Enters Into Licensing Agreement With Biocompatibles International
BTG International Enters Into Licensing Agreement With Onyx Pharma
BTG Enters Into License Agreement With Novacea For AQ4N
BTG Completes Private Placement Of Shares For US$160 Million
MedX Health Acquires Siascopy Assets From BTG For US$0.3 Million
BTG International Sells HySolv Drug Delivery Technology To Novartis Pharma
BTG To Acquire Ekos, Developer Of Drug Delivery System, For US$220 Million
BTG International Acquires Biocompatibles
BTG International Acquires Protherics
Biocompatibles International Completes Acquisition Of BrachySciences For US$21.4 Million
Novartis Acquires Protez Pharma From BTG International

LIST OF FIGURES

BTG plc – Pipeline by Indication, 2013
BTG plc – Pipeline by Stage of Development, 2013
BTG plc – Monotherapy Products in Pipeline, 2013

Ask Your Question

BTG plc – Product Pipeline Review – 2013
Company name*:
Contact person*:
Phone/fax*:
Email*:
Request invoice
Your enquiry: